Mineralys Therapeutics, Inc. - 8-K Filing
Mineralys Therapeutics held its annual meeting on May 21, 2026, where stockholders approved the election of three Class III directors (Srinivas Akkaraju, Brian Taylor Slingsby, Daphne Karydas) and ratified Ernst & Young LLP as their independent auditor. All proposals received a majority vote in favor. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $MLYS